PBC Ireland - Publications

Njei B, Sidney Kanmounye U. 2026. A Multi-Phase Protocol for Developing and Validating an Explainable AI Framework for Continuous Monitoring, Risk Stratification, and Clinical Decision Support in Primary Biliary Cholangitis. JMIR Res Protoc (Apr 2026)

Li H, et al. 2026. Mechanisms linking primary biliary cholangitis and osteoporosis: A combined clinical and molecular analysis. Medicine (Baltimore) (May 2026)

Shang C, et al. 2026. Multilevel Exploration of Shared Genetic Architecture Between Primary Biliary Cholangitis and Four Autoimmune Diseases. Endocr Metab Immune Disord Drug Targets (May 2026)

Trivedi PJ, et al. 2026. Can we cure primary biliary cholangitis? Curr Opin Immunol (Jun 2026)

Gerussi A, et al. 2026. Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: An international expert delphi consensus. Hepatology (May 2026)

Vierling JM, et al. 2026. Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis. Hepatol Commun (Jun 2026)

Chung AH, et al. 2026. Symptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis. Hepatol Commun (Jun 2026)

Granito A, et al. 2026. Primary biliary cholangitis: current insights and novel therapies. Expert Rev Clin Immunol (May 2026)

Chen PT, Chen HW. 2026. Reply to "Comment on 'Risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in Taiwan'". J Formos Med Assoc (May 2026)

Sohal A, et al. 2026. New therapies for primary biliary cholangitis. Hepatol Int (May 2026)

Zhu B, et al. 2026. Molecular mechanisms underlying T cell subset imbalance and precision therapeutic targets in primary biliary cholangitis. Front Pharmacol (2026)

Chen J, et al. 2026. Serum matrix metalloproteinase-7 as a diagnostic and prognostic biomarker in primary biliary cholangitis. Front Med (Lausanne) (2026)

Radice R, et al. 2026. The Role of Laboratory Markers in Primary Biliary Cholangitis: A Clinical Review and a Case Report. Biomedicines (Apr 2026)

Fan Q, Xiong DH. 2026. Comment on "Risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in Taiwan". J Formos Med Assoc (Apr 2026)

Alhaddad O, et al. 2026. Double-barreled drug-induced liver injury and the unmasking of latent primary biliary cholangitis: A case of amoxicillin-clavulanate and warfarin interaction. Arab J Gastroenterol (Apr 2026)

Ogata T, et al. 2026. Dendriform pulmonary ossification in fibrosing interstitial lung disease with primary biliary cholangitis. BMJ Case Rep (Apr 2026)

Wang X, et al. 2026. Clinicopathological features of non-cirrhotic portal fibrosis in primary biliary cholangitis: a 15-year experience at a tertiary referral center. Front Med (Lausanne) (2026)

Ooi QX, et al. 2026. Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis. CPT Pharmacometrics Syst Pharmacol (May 2026)

Angulugaha Gamage CMA, et al. 2026. Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: A Diagnostic Challenge in a Sri Lankan Patient. Cureus (Mar 2026)

Berro M, et al. 2026. Antimitochondrial Antibody-Negative Primary Biliary Cholangitis in a Patient with a History of Colon Cancer and Chemotherapy: A Case Report. Avicenna J Med (Jan 2026)

Caines A, et al. 2026. Author Response to "Comment on Prediagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis". J Gastroenterol Hepatol (Apr 2026)

Liu HL, et al. 2026. Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply. Aliment Pharmacol Ther (Apr 2026)

Jones D, et al. 2026. Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis. J Comp Eff Res (May 2026)

Ruiu A, et al. 2026. From unmet needs to new possibilities: PPAR-targeted therapies in the journey of people living with Primary Biliary Cholangitis. Eur J Intern Med (Apr 2026)

. 2026. Correction to "Characterisation and Clinical Relevance of Tertiary Lymphoid Structures in Primary Biliary Cholangitis". Liver Int (May 2026)

Cheng JS, et al. 2026. Medical Costs Increase Over Time for Primary Biliary Cholangitis Patients: A 20-Year Population-Based Study. Hepatol Res (Apr 2026)

Werner E, et al. 2026. A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation. Aliment Pharmacol Ther (Apr 2026)

Beuers U, et al. 2026. Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis. Hepatol Commun (May 2026)

Gordon SC, et al. 2026. Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies. Hepatol Commun (May 2026)

Antal-Szalmás P, et al. 2026. Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis. J Transl Autoimmun (Jun 2026)

Song Y, et al. 2026. Breaking the metabolo-immune cycle in primary biliary cholangitis for therapeutic benefit. Front Immunol (2026)

Luo J, et al. 2026. [Impact of anti-gp210 and anti-centromere antibody dual positivity on clinical prognosis in patients with primary biliary cholangitis: risk analysis and establishment of response criteria]. Zhonghua Gan Zang Bing Za Zhi (Mar 2026)

Wang W, et al. 2026. Correction: Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia. Front Immunol (2026)

Gao A, et al. 2026. Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Apr 2026)

Levy C, et al. 2026. Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE. Liver Int (May 2026)

Levy C, et al. 2026. Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial. Aliment Pharmacol Ther (Apr 2026)

Ruan F, et al. 2026. Ocular surface characteristics and dry eye symptoms in primary biliary cholangitis patients complicated with seasonal allergic conjunctivitis. Int J Ophthalmol (2026)

Walia N, et al. 2026. The impact of male sex on outcomes in primary biliary cholangitis. Sci Rep (Mar 2026)

Schattenberg JM, et al. 2026. Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis. Aliment Pharmacol Ther (May 2026)

Gainutdin A, et al. 2026. Clinical and Demographic Features of Primary Biliary Cholangitis in Kazakhstan. Diseases (Mar 2026)

Xu Z, et al. 2025. Identification of secretory protein related biomarkers for primary biliary cholangitis based on machine learning and experimental validation. Open Life Sci (2025)

Thalassinos E, et al. 2026. Abnormalities of liver sinusoidal endothelial cells in primary biliary cholangitis. World J Exp Med (Mar 2026)

Lu W, et al. 2026. Hsa_circ_0000711 can serve as a novel biomarker for primary biliary cholangitis by promoting disease progression through the regulation of miR-185-5p and NFATc3. RNA Biol (Dec 2026)

Martins A, et al. 2026. Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis. Aliment Pharmacol Ther (May 2026)

García-Marmolejo JP, et al. 2026. Geographic distribution and demographic patterns of primary biliary cholangitis and autoimmune hepatitis in Colombia: a national population-based administrative study (2018-2024). Ann Gastroenterol (2026)

Dalekos GN, et al. 2026. Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis. Ann Gastroenterol (2026)

. 2026. Correction to "Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER)". United European Gastroenterol J (Mar 2026)

Tana MM, Hirschfield GM. 2026. Primary Biliary Cholangitis and Prognostic Models-Reply. JAMA (Apr 2026)

Leiva-Murillo EA. 2026. Primary Biliary Cholangitis and Prognostic Models. JAMA (Apr 2026)

Liu HL, et al. 2026. Letter: The association between liver biochemistry, biliary and fibrosis in primary biliary cholangitis. Aliment Pharmacol Ther (Jun 2026)

Bossen L, et al. 2026. Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis. Liver Int (Apr 2026)

Liu HL, et al. 2026. Dual Positivity for AMA/AMA-M2 and Anti-gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis. Aliment Pharmacol Ther (Mar 2026)

Csősz J, et al. 2026. [Bullous pemphigoid and primary biliary cholangitis, a rare association with therapeutic challenge]. Orv Hetil (Mar 2026)

Sierra L, et al. 2026. Liver transplant outcomes in primary biliary cholangitis and metabolic dysfunction-associated steatotic liver disease overlap. Ann Hepatol (Mar 2026)

Liu Y, et al. 2025. Risk factors for mortality in patients with primary biliary cholangitis: a nomogram to predict 5-year survival. Front Gastroenterol (Lausanne) (2025)

Li Y, et al. 2026. Integrative Mendelian randomization and experimental validation unveil novel druggable targets in primary biliary cholangitis. Eur J Pharmacol (Apr 2026)

Drazilova S, et al. 2026. Metabolic syndrome and its individual components but not MASLD are associated with advanced fibrosis in primary biliary cholangitis. Ther Adv Gastroenterol (2026)

Dunn S, et al. 2026. Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid. BMJ Open (Mar 2026)

Isakov V, Goncharov A. 2026. Dual cut-offs and beyond: Expanding the role of transient elastography in primary biliary cholangitis. World J Gastroenterol (Feb 2026)

Curto A, et al. 2026. Fatigue and circadian rhythm in non-cirrhotic primary biliary cholangitis: An exploratory comparison with primary sclerosing cholangitis and healthy controls. World J Hepatol (Feb 2026)

Koky T, et al. 2026. Adipokine profiles reflect metabolic dysfunction but not fibrosis in patients with primary biliary cholangitis. World J Hepatol (Feb 2026)

Kawas H, et al. 2026. High-intensity hydrophilic versus lipophilic statins in patients with primary biliary cholangitis: a multi-institutional analysis. BMC Gastroenterol (Mar 2026)

Li SS, et al. 2026. [Positive antinuclear antibodies suggest a high inflammatory burden phenotype: a multicenter retrospective analysis of patients with primary biliary cholangitis]. Zhonghua Gan Zang Bing Za Zhi (Feb 2026)

Nesbitt G, Curley A. 2026. The PBC Ireland patient registry: study protocol for a national platform on primary biliary cholangitis. Ther Adv Rare Dis (2026)

Reddy A, et al. 2026. Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis. Am J Gastroenterol (Mar 2026)

Huang LX, et al. 2026. Pyroptosis Plays a Key Role Through Macrophages in Primary Biliary Cholangitis of Mice. Biomed Res Int (2026)

Silveira IB, et al. 2026. Reconciling the role of ileal bile acid transporter inhibitors as symptom-directed therapy in primary biliary cholangitis: a focused meta-analysis. Eur J Gastroenterol Hepatol (Mar 2026)

Afzal A, et al. 2026. Comments on: Pre-Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis. J Gastroenterol Hepatol (Apr 2026)

Corpechot C, et al. 2026. Reply to 'The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view'. Nat Rev Gastroenterol Hepatol (Apr 2026)

Jones DEJ, et al. 2026. The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view. Nat Rev Gastroenterol Hepatol (Apr 2026)

Gerussi A, Fornai M. 2026. Mechanistic Rationale of Seladelpar's Clinical Efficacy through the Selective PPAR-δ Activation in Primary Biliary Cholangitis. Pharmacol Res (Mar 2026)

Bittermann T, Leonard CE. 2026. Stains in primary biliary cholangitis: Untangling promise from bias. Hepatology (Feb 2026)

Maxwell M, et al. 2026. Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study. Aliment Pharmacol Ther (May 2026)

Bouayad A. 2026. Human leukocyte antigen variants and clinical features of primary biliary cholangitis: Cumulative contributions. World J Clin Cases (Feb 2026)

Gish RG, et al. 2026. Cost of hepatic decompensation and liver transplantation events in primary biliary cholangitis: a retrospective observational study. J Comp Eff Res (Mar 2026)

Papachristou K, et al. 2026. Primary Biliary Cholangitis Pathogenesis: A Pathophysiology-Based Narrative Review. Int J Mol Sci (Jan 2026)

Himoto T, et al. 2026. The Involvement of Apoptosis Inhibitor of Macrophage in the Disease Severity of Primary Biliary Cholangitis. J Clin Med (Feb 2026)

Zhong H, et al. 2026. Primary biliary cholangitis with inflammation involving zone 3 of the liver has a poor response to ursodeoxycholic acid treatment: a retrospective cohort study. BMC Gastroenterol (Feb 2026)

Yang K, et al. 2026. Clinicopathological features of hepatobiliary cells in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. BMC Gastroenterol (Feb 2026)

Xi J, et al. 2026. Exploration and discovery of treatment targets for primary biliary cholangitis based on plasma and cerebrospinal fluid proteomics: A multicenter mendelian randomization study. PLoS One (2026)

Chen S, et al. 2026. Direct bilirubin was superior to total bilirubin in predicting the long-term outcomes of patients with primary biliary cholangitis. BMC Gastroenterol (Feb 2026)

Xu J, et al. 2025. Elevated Serum Soluble Tim-3 in Primary Biliary Cholangitis: Lack of Correlation with Cytokines, Chemokines, and Clinical Parameters. Turk J Gastroenterol (Aug 2025)

Lou J, et al. 2026. Longitudinal multi-omics pilot study: Small sample size human model of gut microbiota-mitochondrial metabolic dysregulation in primary biliary cholangitis. Microbiol Res (Jun 2026)

Yang J, et al. 2026. Primary Biliary Cholangitis-associated Osteoporosis: Contemporary Review of Pathogenesis and Management. J Clin Transl Hepatol (Jan 2026)

Chen R, et al. 2026. A multifaceted analysis of OTUD5 integrated MAVS in innate immunity of Primary Biliary Cholangitis. PLoS One (2026)

Rogalska M, et al. 2026. Lipidome remodeling in primary biliary cholangitis. Lipids Health Dis (Feb 2026)

Su L, et al. 2025. Use of Ursodeoxycholic Acid and Cancer Risk for Patients With Primary Biliary Cholangitis. JAMA Netw Open (Dec 2025)

Choi J, et al. 2026. Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study. Hepatology (Feb 2026)

Buchanan-Peart KA, et al. 2025. Primary Biliary Cholangitis: Novel and Emerging Therapies. Gastroenterol Hepatol (N Y) (Nov 2025)

Lichtenstein GR. 2025. Exploring Current and Emerging Therapies for Patients With Primary Biliary Cholangitis. Gastroenterol Hepatol (N Y) (Nov 2025)

Saeed M, et al. 2025. Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review. Front Med (Lausanne) (2025)

Yoon P, et al. 2026. Alkaline Phosphatase Normalization Occurs Less Frequently in Hispanic Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol (Jan 2026)

Zhou X, et al. 2026. IGFBP4 is a Metric for Primary Biliary Cholangitis and Attenuates Biliary Epithelial Cell Injury. Liver Int (Mar 2026)

Eruzun H, Gronbaek H. 2026. Awareness of Primary Biliary Cholangitis Among Turkish Physicians: A Cross-Sectional, Multicenter, Web-Based Survey. J Clin Med (Jan 2026)

Yang M, et al. 2025. Identification of Differentially Expressed Genes and Molecular Pathways Involved in Primary Biliary Cholangitis Using RNA-Seq. Genes (Basel) (Dec 2025)

Sukubo NG, et al. 2026. Kupffer cell autophagy emerges as a central regulator of immune dysregulation in primary biliary cholangitis. Gut (Jan 2026)

Gordon SC, et al. 2026. Seladelpar Improves Cholestasis and Pruritus in Obeticholic Acid and Fibrate-Experienced Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol (Jan 2026)

Scarlata GGM, Abenavoli L. 2026. The role of gut microbiota in the pathogenesis of primary biliary cholangitis: an immunological perspective. Expert Rev Clin Immunol (Jan 2026)

French J, et al. 2026. Higher sun exposure is associated with a reduced risk of primary biliary cholangitis. Int J Epidemiol (Jan 2026)

(Facebook is for Irish PBC patients only)

Recent News

URSO Calculator

Mar 27th, 2026
PBC Ireland joins the PBC PAG with United Liver

Mar 17th, 2026
PBC Ireland partners with C-PATH

Mar 7th, 2026
PBC Good Care Guide Launched

Feb 4th, 2026
New publication alert in TAIRD!

Jan 1st, 2026
PBC Ireland commences collaboration with C-PATH

Jan 17th, 2026
PBC Ireland to present at Irish Liver Foundation @ Royal College of Surgeons, Ire.

Jan 15th, 2026
PBC Ireland launches their Patient Clinic Visit Questionnaire.

Jul 27th, 2025
The PBC Ireland Patient Registry is now LIVE!

Jul 26th, 2025
PBC Ireland will attend Global Liver Institute's A3 Program in Washington, DC

May 8th, 2025
PBC Ireland Launched!

Publications(100 publications from PubMed)

Recent News

Publications
(100 publications from PubMed)